Potential OAI outcome at FTO-3 facility
FDA issued Form 483 with 10 observations at FTO-3; management has responded but risk of OAI classification could impact approvals and reputation.
high · management_commentary
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
US generic price erosion
Price erosion in US generics continues, though management describes it as stable. Any acceleration could pressure margins.
medium · management_commentaryDependence on Revlimid for cash flows
Revlimid contribution remains meaningful; any unexpected decline could impact cash generation and ability to invest in pipeline.
medium · analyst_questionSupply chain disruptions from Red Sea crisis
Geopolitical tensions are causing sea route disruptions; management is building inventory but costs could rise if situation persists.
low · analyst_question